RopesTalk

The Ropes & Gray Decoding Digital Health podcast series discusses the digital health industry and related legal, business and regulatory issues. On this episode, Digital Health Initiative co-lead and IP transactions partner, Megan Baca, is joined by Verily Life Sciences Lead Product Counsel, John Vaughan, to continue their discussion on Verily’s innovative partnerships in digital health, the challenges Verily has faced as well as the rewarding solutions that Verily and its partnerships have created.

In this episode of Trainee Insights, Ropes & Gray director of human resources, Beverley Sorsby, shares her experience of nine years at Ropes & Gray in London. Beverley speaks about the nature of the trainee recruitment process, provides insights into the upcoming recruitment campaign, and discusses what Ropes & Gray looks for in prospective applicants.

Welcome to the R&G Tech Studio, a Ropes & Gray podcast series highlighting the firm’s technology attorneys, their respective practice areas and how the ever-changing tech landscape impacts their clients. On this inaugural episode, private equity partner Scott Abramowitz sits down to discuss his practice and how the fintech industry has evolved with TMT co-lead Ed Black.

The Ropes & Gray Decoding Digital Health podcast series discusses the digital health industry and related legal, business and regulatory issues. On this episode, Digital Health Initiative co-lead and IP transactions partner, Megan Baca, is joined by Verily Life Sciences Lead Product Counsel, John Vaughan, for a two-part discussion on digital health dealmaking. Megan and John dive into topics related to partnership strategies between biopharma and tech companies, as well as the key opportunities and challenges associated with digital health innovation deals.

The Ropes & Gray Decoding Digital Health podcast series discusses the digital health industry and related legal, business and regulatory issues. On this episode, Digital Health Initiative co-lead and IP transactions partner, Megan Baca, is joined by Verily Life Sciences Lead Product Counsel, John Vaughan, for a two-part discussion on digital health dealmaking. Megan and John dive into topics related to partnership strategies between biopharma and tech companies, as well as the key opportunities and challenges associated with digital health innovation deals.

In this Ropes & Gray podcast, finance partner Alyson Gal and associate Andy Hogan discuss the use of credit facilities as an important source of liquidity and leverage for registered investment funds. They explore the regulatory landscape applicable to these facilities and review some of their key terms.

In this episode of Women @ RopesTalk, hosted by IP transactions partner Megan Baca, IP transactions attorney Georgina Suzuki interviews Christina Carlson, general counsel of HI-Bio, a biotechnology company focused on discovering and developing precision medicines for autoimmune and inflammatory diseases. Christina talks about her move from Gilead Sciences, where she oversaw corporate legal, to HI-Bio, where she has a more legal generalist role. In thinking about her 15-plus-year career, which includes roles at a law firm and in-house, she dispels misconceptions she once had about networking and gives advice for those who wish to follow in her footsteps. For lawyers or others considering careers in biotech, Christina reflects on the exciting and inspiring work she’s contributed to in the areas of HIV and COVID.

In this Ropes & Gray podcast, Doug Brayley, employment partner and head of the employment litigation practice, and Greg Demers, counsel in the employment practice, speak with Dan Murphy, an employment, executive compensation & employee benefits associate, about recent legal trends related to the enforceability of restrictive covenants, particularly non-competition agreements, and considerations for employers going forward.

Following the recent publication relating to continued global pressure on drug pricing, this episode of Ropes & Gray’s podcast series Non-binding Guidance focuses on the significant changes to global business and legal environments for drug pricing brought about by the COVID-19 pandemic and the impacts on the pharmaceutical supply chain and patient access to innovative cutting-edge therapies. Hear from Ropes & Gray’s head of European life sciences practice Lincoln Tsang and health care partner Margaux Hall as they discuss the trend of rising health care drug costs in the U.S. and the UK, significant implications of the Inflation Reduction Act and similar drug pricing policy in the countries outside the U.S., the increasing role of real-world evidence in decision making, and impacts from these changes across the U.S., Europe and worldwide.